Nephrologist Kathleen Liu, MD, PhD, MAS, Professor of Medicine and Anesthesia at the University of California, San Francisco, will be the guest speaker at the 2024 Eduardo Slatopolsky Lectureship in Renal and Electrolyte Disorders.
The event will be held at Medicine Grand Rounds, Thursday, March 21, at 8am in Clopton Auditorium. Dr. Liu will discuss “Post-AKI Care.”
Dr. Liu’s current research focuses on the predictive and pathogenetic role of biomarkers for both acute and chronic disease states. The long-term goal is to identify and validate novel biomarkers of organ injury (specifically, the kidney and lung) that may have predictive value for disease outcomes as well as shed important insight into disease pathogenesis.
She is currently involved in the START (STem cells for ARDS Treatment) clinical trial for the treatment of patients with Acute Respiratory Distress Syndrome (ARDS). Preclinical studies have shown that mesenchymal stem cells are effective at reducing the severity of organ injury as well as enhancing recovery. This is the first clinical trial to use mesenchymal stem cells as a treatment for patients with severe ARDS.
The lectureship honors Eduardo Slatopolsky, MD, Professor Emeritus, WashU Nephrology, who dedicated his career to the study of kidney disease and mineral metabolism. He is recognized worldwide for his contributions to the understanding of the pathophysiology of secondary hyperparathyroidism, hyperphosphatemia and vitamin D biology.
On X, follow @LiuKD and @WUNephrology; visit and “Like” us on Facebook.
